Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.67 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174318 | 0.93 | PTGDR2 (0.71) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL3166257 | 0.90 | PTGDR2 (0.75) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL3168783 | 0.90 | PTGDR2 (0.75) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL27866946 | 0.85 | PTGDR2 (0.71) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL3177154 | 0.84 | PTGDR2 (0.68) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL27866947 | 0.83 | PTGDR2 (0.69) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL3168673 | 0.83 | PTGDR2 (0.94) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL3177159 | 0.83 | PTGDR2 (0.68) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL3172703 | 0.81 | PTGDR2 (0.72) | PTGDR2PTGDRPDE4APDE4BPDE4C | |
| SCHEMBL3164718 | 0.80 | PTGDR2 (1.00) | PTGDR2PTGDRPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885PTGDR 189/4885PDE4A 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.